CD4+ T cells are a primary mediator of immunopathology in T1D; therefore, we wanted to determine if inhibiting metabolic reprogramming by MnP treatment reduced their diabetogenic potential. The gene discussed is CD4; the disease is type 1 diabetes mellitus.